How I treat patients who are refractory to platelet transfusions

Patients with thrombocytopenia requiring ongoing platelet transfusion support may develop inadequate platelet count increments, referred to as platelet refractoriness (PR), which further complicates their care. The underlying etiologies of PR can be broadly divided into immune and nonimmune causes....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood Jg. 145; H. 20; S. 2293
Hauptverfasser: Nahirniak, Susan, Nadarajan, Veera, Stanworth, Simon J
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 15.05.2025
Schlagworte:
ISSN:1528-0020, 1528-0020
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Patients with thrombocytopenia requiring ongoing platelet transfusion support may develop inadequate platelet count increments, referred to as platelet refractoriness (PR), which further complicates their care. The underlying etiologies of PR can be broadly divided into immune and nonimmune causes. A high index of suspicion is required to initiate testing for alloimmunization, and the leading culprit in immune PR is the development of class I HLA antibodies. The approach to diagnosis of immune PR has changed over recent years with new technologies, but questions regarding the clinical significance and interpretation of these methods have not been conclusively answered. The provision of HLA-matched platelets requires close and timely coordination between transfusion services and clinical teams; however, the true impact of their provision on clinical outcomes is not clear. This paper reviews diagnostic and management challenges, appraises the existing data available to support treatment options, and identifies research gaps.
AbstractList Patients with thrombocytopenia requiring on-going platelet transfusion support may develop inadequate platelet count increments, referred to as Platelet Refractoriness (PR), which further complicates their care. The underlying etiologies of PR can be broadly divided into immune and non-immune causes. A high index of suspicion is required to initiate testing for alloimmunization and t leading culprit in immune PR is development of Class I Human Leukocyte Antigens (HLA) antibodies. The approach to diagnosis of immune PR has changed over the recent years with new technologies but questions regarding clinical significance and interpretation of these methods have not been conclusively answered. The provision of HLA-matched platelets requires close and timely co-ordination between transfusion services and clinical teams; however, the true impact of their provision on clinical outcomes is not clear. This paper will review diagnostic and management challenges, appraise the existing data available to support treatment options, and identify research gaps.Patients with thrombocytopenia requiring on-going platelet transfusion support may develop inadequate platelet count increments, referred to as Platelet Refractoriness (PR), which further complicates their care. The underlying etiologies of PR can be broadly divided into immune and non-immune causes. A high index of suspicion is required to initiate testing for alloimmunization and t leading culprit in immune PR is development of Class I Human Leukocyte Antigens (HLA) antibodies. The approach to diagnosis of immune PR has changed over the recent years with new technologies but questions regarding clinical significance and interpretation of these methods have not been conclusively answered. The provision of HLA-matched platelets requires close and timely co-ordination between transfusion services and clinical teams; however, the true impact of their provision on clinical outcomes is not clear. This paper will review diagnostic and management challenges, appraise the existing data available to support treatment options, and identify research gaps.
Patients with thrombocytopenia requiring ongoing platelet transfusion support may develop inadequate platelet count increments, referred to as platelet refractoriness (PR), which further complicates their care. The underlying etiologies of PR can be broadly divided into immune and nonimmune causes. A high index of suspicion is required to initiate testing for alloimmunization, and the leading culprit in immune PR is the development of class I HLA antibodies. The approach to diagnosis of immune PR has changed over recent years with new technologies, but questions regarding the clinical significance and interpretation of these methods have not been conclusively answered. The provision of HLA-matched platelets requires close and timely coordination between transfusion services and clinical teams; however, the true impact of their provision on clinical outcomes is not clear. This paper reviews diagnostic and management challenges, appraises the existing data available to support treatment options, and identifies research gaps.
Author Nadarajan, Veera
Nahirniak, Susan
Stanworth, Simon J
Author_xml – sequence: 1
  givenname: Susan
  orcidid: 0000-0002-2895-4805
  surname: Nahirniak
  fullname: Nahirniak, Susan
  organization: Department of Laboratory Medicine and Pathology, Faculty of Medicine, University of Alberta, Edmonton, AB, Canada
– sequence: 2
  givenname: Veera
  surname: Nadarajan
  fullname: Nadarajan, Veera
  organization: Department of Preclinical Sciences, Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Kajang, Malaysia
– sequence: 3
  givenname: Simon J
  orcidid: 0000-0002-7414-4950
  surname: Stanworth
  fullname: Stanworth, Simon J
  organization: NHS Blood and Transplant, Oxford, United Kingdom
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39970326$$D View this record in MEDLINE/PubMed
BookMark eNpNz89LwzAcBfAgE_dD754kRy-dyTdJm9yUoW4w8KLn8m33LVa6piYpY_-9Ayd4eu_w4cGbs0nve2LsVoqllBYeqs773RIEKAFgrbpgM2nAZkKAmPzrUzaP8UsIqRWYKzZVzhVCQT5jj2t_4BueAmHiA6aW-hT54dNzDMQDNQHr5MORJ8-HDhN1lE4a-9iMsfV9vGaXDXaRbs65YB8vz--rdbZ9e92snrZZrQykTGrKC-PAGecsSOMwL6qmqbWRtm5cgaiFtEILZWVl7E5XOaKRtZaVIKUrWLD7390h-O-RYir3bayp67AnP8ZSydwWubWgT_TuTMdqT7tyCO0ew7H8ew0_EXdapA
CitedBy_id crossref_primary_10_1016_j_humimm_2025_111570
crossref_primary_10_36283_ziun_pjmd14_2_055
crossref_primary_10_1186_s43054_025_00407_1
ContentType Journal Article
Copyright 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Copyright © 2025 American Society of Hematology.
Copyright_xml – notice: 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
– notice: Copyright © 2025 American Society of Hematology.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1182/blood.2023022883
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
Anatomy & Physiology
EISSN 1528-0020
ExternalDocumentID 39970326
Genre Journal Article
Review
GroupedDBID ---
-~X
.55
0R~
23N
2WC
34G
39C
4.4
5GY
5RE
6J9
AAEDW
AALRI
AAXUO
ABOCM
ACGFO
ACVFH
ADBBV
ADCNI
AENEX
AFETI
AFOSN
AGCQF
AITUG
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BAWUL
BTFSW
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EFKBS
EIF
EJD
EX3
F5P
FDB
FRP
GS5
GX1
H13
IH2
K-O
KQ8
L7B
LSO
MJL
N9A
NPM
OK1
P2P
R.V
RHI
ROL
SJN
THE
TR2
TWZ
W2D
WH7
WOQ
WOW
X7M
YHG
YKV
7X8
ID FETCH-LOGICAL-c352t-14e67592959982159a67bffc4518cf97aa4018040381b58d4b6aa51c41b0e34b2
IEDL.DBID 7X8
ISICitedReferencesCount 3
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001503924400005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1528-0020
IngestDate Sun Nov 09 11:03:56 EST 2025
Mon Jul 21 06:02:06 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 20
Language English
License 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c352t-14e67592959982159a67bffc4518cf97aa4018040381b58d4b6aa51c41b0e34b2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-7414-4950
0000-0002-2895-4805
PMID 39970326
PQID 3168768824
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3168768824
pubmed_primary_39970326
PublicationCentury 2000
PublicationDate 2025-05-15
PublicationDateYYYYMMDD 2025-05-15
PublicationDate_xml – month: 05
  year: 2025
  text: 2025-05-15
  day: 15
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Blood
PublicationTitleAlternate Blood
PublicationYear 2025
SSID ssj0014325
Score 2.4967258
SecondaryResourceType review_article
Snippet Patients with thrombocytopenia requiring ongoing platelet transfusion support may develop inadequate platelet count increments, referred to as platelet...
Patients with thrombocytopenia requiring on-going platelet transfusion support may develop inadequate platelet count increments, referred to as Platelet...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 2293
SubjectTerms Blood Platelets - immunology
Humans
Platelet Count
Platelet Transfusion - methods
Thrombocytopenia - diagnosis
Thrombocytopenia - immunology
Thrombocytopenia - therapy
Title How I treat patients who are refractory to platelet transfusions
URI https://www.ncbi.nlm.nih.gov/pubmed/39970326
https://www.proquest.com/docview/3168768824
Volume 145
WOSCitedRecordID wos001503924400005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFH6odbu4tC51YwTxFptlsp20FksFW3pQ6a3MJBMUNKlNa-m_971pQk-C4CUkkIHkzfK-t_B9AFdJzEMpzdBIlCsMLqzYEAKDFfT0MT6ImOuc7uuT3-sFg0HYLxJuedFWWZ6J-qCOs4hy5A0SWEJoHNj8dvRlkGoUVVcLCY1VqDgIZWhj-oNlFYE7WnQVXVRgEC4qy5SB3dBt4TekHU4EMEQa-BvA1I6mvfvfT9yDnQJisuZiTezDikqrUGumGF5_ztk1002fOptehY378m6rVUq_VWGzW1Tca3DXyWbskel-dFaQsOZs9pYxMVYM3etYC_bM2SRjow8ErrgO8G1Cw1NKxOUH8NJ-eG51jEJ1wYgQjE0MiysMIhA1uRiJISAIhefLJIm4awVREvpCcCL94lRilG4Qc-kJ4VoRt6SpHC7tQ1hLs1QdAws8NEcoidMv5I4npUoiW_iCcxNHmnEdLktDDvEPqVQhUpVN8-HSlHU4WszGcLSg3xgipMJjyvZO_jD6FLZtEuwlulX3DCoJ7ml1DuvR9-Q9H1_o5YLXXr_7Aym4yLM
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=How+I+treat+patients+who+are+refractory+to+platelet+transfusions&rft.jtitle=Blood&rft.au=Nahirniak%2C+Susan&rft.au=Sekaran+Nadarajan%2C+Veera&rft.au=Stanworth%2C+Simon+J&rft.date=2025-05-15&rft.issn=1528-0020&rft.eissn=1528-0020&rft_id=info:doi/10.1182%2Fblood.2023022883&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-0020&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-0020&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-0020&client=summon